Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204317 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL8871035 | 0.79 | CES2 (0.55) | PARP1ALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL9448999 | 0.79 | PARP1 (0.52) | PARP1ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL8715637 | 0.79 | ALDH1A1 (0.53) | PARP1ALDH1A1MAPTHTTMEN1 | |
| SCHEMBL9449177 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HTTMEN1 | |
| SCHEMBL1927123 | 0.77 | KMO (0.55) | ALDH1A1MAPTHTTMEN1KMT2A | |
| SCHEMBL3059556 | 0.77 | PARP1 (0.59) | PARP1ALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL9448994 | 0.77 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL82420 | 0.77 | ALDH1A1 (0.60) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| Water SCHEMBL8938106 | 0.76 | PARP1 (0.57) | PARP1ALDH1A1MAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840504-B2 | Method for preparing perfluoroalkyl sulfinate ester | SOOCHOW UNIVERSITY (CN) | 2023-12-12 | — | — | US | disclosed |
| CN-113248458-B | Preparation method of alpha-carbonyl amide compound | 陕西省煤田地质集团有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-113248458-A | Preparation method of alpha-carbonyl amide compound | 陕西省煤田地质集团有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | disclosed |
| US-8846658-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CN) | 2014-04-24 | — | — | US | disclosed |
| US-20140088084-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | HOLZER PHILIPP (CH) | 2014-03-27 | — | — | US | disclosed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG | 2011-01-27 | — | — | US | disclosed |
| WO-2011009943-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
| US-5693648-A | TREATMENT OF AUTOIMMUNE DISEASES, INFECTIOUS DISEASES, PREVENTING REJECTION OF ORGAN TRANSPLANTS | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5565560-A | TREATING AUTOIMMUNE DISEASES, PREVENTING TRANSPLANT REJECTION | MERCK & CO., INC. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5532248-A | O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity | MERCK CO., INC. (US) | 1996-07-02 | — | — | US | disclosed |
| WO-1995009857-A1 | O-ARYL, O-ALKYL, O-ALKENYL AND O-ALKYNYL-MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0466730-B1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1993-07-21 | — | — | EP | disclosed |
| US-5220021-A | Geminal bisphosphonic acids and derivatives as anti-arthritic agents | THE UPJOHN COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0466730-A1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS. | UPJOHN CO (US) | 1992-01-22 | — | — | EP | disclosed |
| WO-1990012017-A1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | PARP1 2484/4885ALDH1A1 2685/4885MAPT 69/4885 |
| US-20140088084-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | PARP1 4628/4885ALDH1A1 508/4885MAPT 45/4885 |
| US-20110021520-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | PARP1 4628/4885ALDH1A1 508/4885MAPT 45/4885 |
| US-11840504-B2 | Method for preparing perfluoroalkyl sulfinate ester | TERT, TST, CTH | PARP1 2825/4885ALDH1A1 210/4885MAPT 1874/4885 |
| US-20140113894-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | PARP1 4628/4885ALDH1A1 508/4885MAPT 45/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | PARP1 4628/4885ALDH1A1 508/4885MAPT 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.